Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression

By Fleishaker J.C.  

Clinical Pharmacokinetics, Vol. 39, Iss. 6, 2000-12 ,pp. : 413-427

Adis International

Access to resources Recommend Favorite

Reboxetine: the first selective noradrenaline re-uptake inhibitor

By Kasper S.   Giamal N.E.   Hilger E.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 771-782

Informa Healthcare

Access to resources Recommend Favorite

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor

By Kielbasa William   Tesfaye Eshetu   Luffer-Atlas Debra   Mitchell Malcolm   Turik Michael  

European Journal of Clinical Pharmacology, Vol. 69, Iss. 12, 2013-12 ,pp. : 2011-2019

Springer Publishing Company

Access to resources Recommend Favorite

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

By Nichols Alice I   Tourian Karen A   Tse Susanna Y   Paul Jeffrey  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 12, 2010-12 ,pp. : 1565-1574

Informa Healthcare

Access to resources Recommend Favorite

Serotonin-Norepinephrine Reuptake Inhibitor Antidepressants and the Risk of Falls in Older People: Case-Control and Case-Series Analysis of a Large UK Primary Care Database

By Gribbin Jonathan  

Drugs & Aging, Vol. 28, Iss. 11, 2011-11 ,pp. : 895-902

Adis International

Access to resources Recommend Favorite